This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Oncology Consults: Addressing Unmet Needs in Mesothelioma: Evaluating the Role of Angiokinase Inhibitors

Oncology Consults: Addressing Unmet Needs in Mesothelioma: Evaluating the Role of Angiokinase Inhibitors

Format

Patient Case Study

Time to Complete

30 minutes

Released

March 8, 2018

Expires

March 8, 2019
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM
0.50 / CNE Contact Hour

Accredited Providers

Presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.

Commercial Supporter

Supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc.

Program Description

Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Recently, a growing body of research has demonstrated that angiogenesis is an important part of the pathophysiology for many types of cancer, including MPM, and angiogenesis inhibitors have increasingly been used to treat patients with MPM. Although not yet approved by the US Food and Drug Administration (FDA), evidence-based guidelines recommend the addition of the anti-angiogenesis agent bevacizumab, to pemetrexed and cisplatin for select MPM patients. Several oral angiogenesis inhibitors (also referred to as angiokinase inhibitors) are being developed for treating patients with MPM. This activity will explore the challenges in the current care of patients with MPM and prospects for improved, more personalized therapy approaches in the future.

Intended Audience

This activity is designed for oncology physicians, physician assistants, nurse practitioners, and nurses who manage patients with MPM. No prerequisites required.

Educational Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • RECOGNIZE clinical challenges and unmet needs associated with MPM diagnosis and treatment.
  • DESCRIBE the role of and rationale for targeting angiogenesis in MPM.
  • EVALUATE available data and potential clinical implications of investigational angiokinase inhibitors for MPM.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category I Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CNE Contact Hour(s)

Accreditation Statement

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This 0.50 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until March 8, 2019.

Policy On Speaker and Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine (and the Institute for Johns Hopkins Nursing) that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

Full Disclosure Policy Affecting CME Activities

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

Planner Disclosures

Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving as a consultant for AbbVie Inc, BeyondSpring Pharmaceuticals, Inc, Boehringer-Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, Guardant Health Inc, Genentech Inc, Helsinn Therapeutics Inc, Herron Therapeutics, and Sanofi-aventis, US LLC.

Dr. Forde reports service as principal investigator for Bristol-Myers Squibb; AstraZeneca; Novartis; Kyowa. Uncompensated Advisor for Boehringer Ingelheim; Vetmedica; Celgene; AstraZeneca; Bristol-Myers Squibb; Aventis; Novartis.


No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Faculty

Chair and Planner
David S. Ettinger, MD

Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Faculty Author
Patrick Forde, MBBCh

Assistant Professor of Oncology
Johns Hopkins University School of Medicine
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Nurse Planner
Rebecca Barshick, RN, MSN

Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, MD

Nurse Reviewer
MiKaela Olsen APRN-CNS, MS, AOCNS, FAAN

Oncology and Hematology Clinical Nurse Specialist
Ambulatory Oncology
Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins Hospital and Greenspring Oncology
Baltimore, MD

Off-Label Product Discussion

The activity chair has disclosed this module will reference the following unlabeled/unapproved uses of drugs or products:

  • Cediranib
  • Nintedanib

Non-Endorsement of Products

The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Instructions

The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact the CME Office 410-955-2959 or email cmenet@jhmi.edu.

Confidentiality Disclaimer for CME Activity Participant

I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

For CME questions, please contact the CME Office 410-955-2959 or email cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)


myCME privacy policy

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT

The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue